InventisBio (SH:688382)2024-04-29 08:28Financial Performance - The company's operating revenue for Q1 2024 was CNY 8,606,045.10, with a significant reliance on technology licensing and collaboration income [5]. - The net profit attributable to shareholders was a loss of CNY 83,177,667.08, indicating ongoing financial challenges [5]. - The net cash flow from operating activities was negative at CNY -89,720,647.28, reflecting cash outflows during the quarter [5]. - Total revenue for Q1 2024 was CNY 8,606,045.10, compared to CNY 0 in Q1 2023 [16]. - Net loss for Q1 2024 was CNY 83,177,667.08, compared to a net loss of CNY 117,870,350.59 in Q1 2023, showing an improvement of approximately 29.3% [17]. - Total comprehensive income for Q1 2024 was a loss of ¥83,771,183.23, compared to a loss of ¥117,451,215.04 in Q1 2023, indicating a reduction in losses of about 28.7% [18]. - Basic and diluted earnings per share for Q1 2024 were both -¥0.14, an improvement from -¥0.20 in Q1 2023 [18]. Research and Development - Research and development expenses totaled CNY 84,752,226.60, accounting for an extraordinary 984.80% of operating revenue, a decrease of 23.07% compared to the previous year [6]. - R&D expenses for Q1 2024 were CNY 84,752,226.60, down from CNY 110,164,964.97 in Q1 2023, indicating a decrease of about 23.1% [17]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 2,076,769,526.09, down 3.95% from the previous year [6]. - Total assets decreased to CNY 2,076,769,526.09 from CNY 2,162,272,043.34, reflecting a decline of about 4.0% [13]. - Total liabilities decreased to CNY 142,133,254.45 from CNY 164,669,523.57, a reduction of approximately 13.7% [14]. - The company's equity attributable to shareholders decreased to CNY 1,934,636,271.64 from CNY 1,997,602,519.77, a decline of about 3.2% [14]. - The company reported a decrease in accounts payable from CNY 72,521,670.83 to CNY 58,137,728.24, a reduction of approximately 19.9% [13]. - The company’s long-term assets totaled CNY 36,951,398.91, down from CNY 39,151,100.07, indicating a decrease of about 5.6% [13]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 13,691 [9]. - The largest shareholder, InventisBio Hong Kong Limited, held 19.13% of the shares, totaling 110,329,937 shares [9]. - There were no significant changes in the shareholding structure of the top ten shareholders compared to the previous period [10]. Cash Flow - Cash and cash equivalents as of March 31, 2024, were CNY 1,837,074,642.19, down from CNY 1,919,444,422.57 at the end of 2023 [12]. - Cash inflows from operating activities totaled ¥5,819,313.65 in Q1 2024, down from ¥6,175,514.74 in Q1 2023 [20]. - Cash outflows from operating activities increased to ¥95,539,960.93 in Q1 2024, compared to ¥87,849,840.57 in Q1 2023, resulting in a net cash flow from operating activities of -¥89,720,647.28 [20]. - Cash and cash equivalents at the end of Q1 2024 were ¥1,129,626,308.86, down from ¥1,645,819,421.57 at the end of Q1 2023 [21]. - The company raised ¥7,215,958.35 from financing activities in Q1 2024, compared to a net outflow of -¥3,848,655.96 in Q1 2023 [21]. - The net cash flow from financing activities for Q1 2024 was ¥4,734,864.59, a significant turnaround from the previous year's negative cash flow [21]. - The company reported a cash flow impact from exchange rate changes of -¥365,816.87 in Q1 2024, compared to -¥1,910,163.60 in Q1 2023 [21]. Product Development - The company did not report any significant new product developments or market expansions during this quarter [22].